(Q37074126)

18 August 2017

1 reference

title

The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer (English)

1 reference

18 August 2017

1 reference

1 reference

Stefan Boeck

1

1 reference

18 August 2017

Volker Heinemann

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

41-50

1 reference

18 August 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Prognostic factors in patients with gemcitabine-refractory pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

End points in advanced colon cancer clinical trials: a review and proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Phase II trial of oral rubitecan in previously treated pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Importance of performance status for treatment outcome in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.41

21 January 2018

Identifiers

DOI

10.2217/14796694.4.1.41

1 reference

18 August 2017

1 reference